Approval · Notice of Compliance 32208 · 2023
CLAVULIN: Notice of Compliance 32208
Issued November 29, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32208
- Date
- November 29, 2023
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety update to the product monograph initiated by the Sponsor.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CLAVULIN | Not yet assigned | — |
Medicinal ingredients
- CLAVULANATE POTASSIUM 125 MG per TAB
- AMOXICILLIN TRIHYDRATE 500 MG per TAB
- AMOXICILLIN TRIHYDRATE 875 MG per TAB
- CLAVULANATE POTASSIUM 31.25 5ML per TAB
- AMOXICILLIN TRIHYDRATE 125 5ML per TAB
- CLAVULANATE POTASSIUM 28.5 5ML per TAB
- AMOXICILLIN TRIHYDRATE 200 5ML per TAB
- CLAVULANATE POTASSIUM 62.5 5ML per TAB
- AMOXICILLIN TRIHYDRATE 250 5ML per TAB
- CLAVULANATE POTASSIUM 57 5ML per TAB
- AMOXICILLIN TRIHYDRATE 400 5ML per TAB